Rchr
J-GLOBAL ID：201501044476136051
Update date: Apr. 23, 2024
Haratani Koji
Haratani Koji | Haratani Koji
Affiliation and department：
Job title：
Research Fellow
Other affiliations (1)：
Research theme for competitive and other funds (2)：
- 2019 - 2022 Immune related gene-expression profiling for the combination of chemotherapy and PD-1/PD-L1 inhibition.
- 2019 - 2021 The association of tumor burden and anti-PD-1 inhibitor therapy efficacy in patients with untreated advanced non-small cell lung cancer.
Papers (93)：
-
Hidetoshi Hayashi, Kenji Chamoto, Ryusuke Hatae, Takashi Kurosaki, Yosuke Togashi, Kazuya Fukuoka, Megumi Goto, Yasutaka Chiba, Shuta Tomida, Takayo Ota, et al. Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade. Journal of Clinical Investigation. 2024. 134. 7
-
Koji Haratani(*Corresponding author), Atsushi Nakamura, Nobuaki Mamesaya, Kenji Sawa, Yoshimasa Shiraishi, Ryota Saito, Junko Tanizaki, Yosuke Tamura, Akito Hata, Kosuke Tsuruno, et al. Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer. British journal of cancer. 2024
-
Tetsuo Tani, Haritha Mathsyaraja, Marco Campisi, Ze-Hua Li, Koji Haratani, Caroline G Fahey, Keiichi Ota, Navin R Mahadevan, Yingxiao Shi, Shin Saito, et al. TREX1 inactivation unleashes cancer cell STING-interferon signaling and promotes anti-tumor immunity. Cancer discovery. 2024
-
Takeshi Masuda, Satoru Miura, Yuki Sato, Motoko Tachihara, Akihiro Bessho, Atsushi Nakamura, Taichi Miyawaki, Kohei Yoshimine, Masahide Mori, Hideaki Shiraishi, et al. Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer. Scientific Reports. 2023. 13. 1
-
Takehiro Uemura, Hirotsugu Kenmotsu, Daisuke Hazama, Shunsuke Teraoka, Hiroshi Kobe, Koichi Azuma, Teppei Yamaguchi, Takeshi Masuda, Toshihide Yokoyama, Kohei Otsubo, et al. Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single-plex testing: WJOG13620L. Cancer medicine. 2023
ｍore...
MISC (55)：
-
磯本晃佑, 原谷浩司, 田中薫, 谷崎潤子, 高濱隆幸, 金村宙昌, 鈴木慎一郎, 林秀敏. 腫瘍微小環境における免疫細胞の局在と免疫チェックポイント阻害薬の効果との関連. 日本肺癌学会学術集会号. 2023. 64th (CD-ROM)
-
中村敦, 坂田晋也, 大坪孝平, 伊藤健太郎, 寺岡俊輔, 松本直久, 白石祥理, 原谷浩司, 田宮基裕, 池田慧, et al. A multicenter retrospective study of Oncomine Dx Target Test Multi-CDx system for genetic profiling of NSCLC: WJOG13019L (DETECT-LC). 日本呼吸器学会誌(Web). 2021. 10
-
加藤了資, 林秀敏, 原谷浩司, 高濱隆幸, 谷崎潤子, 野長瀬祥兼, 田中薫, 吉田健史, 武田真幸, 米阪仁雄, et al. CAPP-Seqを用いたLiquid biopsyによるT790M陽性非小細胞肺癌のオシメルチニブ耐性因子の検討. 肺癌(Web). 2020. 60. 2
-
鈴木慎一郎, 原谷浩司, 加藤了資, 林秀敏, 中川和彦, 谷崎潤子, 尾崎智博, 岡部崇記, 明石雄策, 長谷川喜一, et al. PD-L1高発現未治療進行非小細胞肺癌におけるPembrolizumabの治療効果と総腫瘍量の関連性. 肺癌(Web). 2020. 60. 2
-
西山 理, 佐野 安希子, 林 秀敏, 西川 裕作, 谷崎 潤子, 原谷 浩司, 中川 和彦, 東田 有智. 免疫治療の有害事象対策 間質性肺炎発症のリスク評価とその対策. 肺癌. 2019. 59. 6. 547-547
ｍore...
Work history (2)：
- 2021/03 - 現在 Dana-Farber Cancer Institute (Dana-Ferber/Harvard Cancer Center) Department of Medical Oncology Research Fellow
- 2015/04 - 2023/04 Kindai University Faculty of Mediciine Department of Medical Oncology Assistant Professor
Awards (4)：
- 2021/02 - Japanese Society of Medical Oncology Annals of Oncology Award
- 2018/12 - 日本肺癌学会 日本肺癌学会若手奨励賞
- 2018/07 - 日本臨床腫瘍学会 日本臨床腫瘍学会奨励賞
- 2018/03 - 近畿大学 学長賞
Association Membership(s) (4)：
ACP
, ASCO
, 日本臨床腫瘍学会
, THE JAPANESE SOCIETY OF INTERNAL MEDICINE
